A B STR A C T
In this study 19 patients w ere preoperatively treated w ith octreotide for 1-17 months (mean, 5 months), w ith doses from 150-1500 µg daily, and those patients w ere matched to 19 untreated patients w ith comparable tumor classifi cation and preoperative serum G H concentrations. O ctreotide w as started at 300 µg daily by sc injections or continuous sc infusion using a pump in increasing doses, depending on the responses of the serum G H and insulin-like A djuvant therapy w as required in 7 treated and 5 untreated patients. A t follow -up examination, 5.7 and 4 yr postoperatively, 10 pretreated and 12 control patients could be considered cured by surgery only, according to our criteria for remission (serum G H, < 5 mU /L; normal G H suppression and normal serum IG F-I). In summary, w e found no diff erence in direct postoperative and follow -up results of transsphenoidal surgery betw een pretreated patients and untreated patients. This fi nding is in discordance w ith other studies, w hich have claimed a benefi cial eff ect of octreotide pretreatment.
IN TRO DU CTIO N
TRANSSPHENOIDAL SURGERY USING M ICROSURGICAL TECHNIQ UES is accepted as the treatment of choice for GH-secreting pituitary adenomas; surgical cure rates in the literature range from 30-75% depending on the criteria used. Those results are more favorable for microadenomas (± 70% ) than for invasive macroadenomas (45% ). Tumor size has been found to be a preoperative prognostic factor (1) . Another preoperative factor that has been claimed to predict outcome after surgery is the preoperative GH level (2) . The importance of reducing GH levels to normal was emphasized by Bates et al., who found a higher mortality rate in a group with elevated GH levels compared with that in a group with GH levels below 5 mU/L (3).
Octreotide, a long acting somatostatin analog, is eff ective in suppressing GH and insulin- As most reported studies were rather small and were made in retrospect, we devised a prospective study in which not only direct postoperative results but also long term results were evaluated. The criteria we applied for cure are in line with generally accepted rules, i.e. random GH below 5 mU/L, glucose-suppressed GH values based on validated normal values in healthy controls, and normal serum IGF-I concentrations. W e also aimed to investigate whether there were diff erences in the incidence of (surgical) complications, hypopituitarism, or duration of neurosurgical hospital stay.
SU BJECT AN D M ETH O DS

Patients
Between 1988 and 1996, 57 acromegalic patients were referred to the Leiden University fered to all patients, and after full explanation of the aim of the study and the possible eff ects and side-eff ects of octreotide treatment, 19 patients agreed to pretreatment.
These patients (10 males and 9 females) were compared to 19 nontreated patients selected from the above-mentioned group of 57 patients. Those patients were matched individually to the pretreated group primarily by tumor class and grade and secondarily by preoperative GH concentration. The mode of administration of octreotide, either by 3 daily sc injections or by continuous sc infusion, depended on the fully informed patient' s preference.
Octreotide treatment was started at a daily dose of 300 µg, and treatment was evaluated by measuring GH levels. The dose was increased or decreased as necessary depending on the GH concentration; individual doses ranged from 150-1500 µg daily, the mean daily dose was 529 ± 83 µg. GH and IGF-I concentrations were obtained at 1, 3, and 4 months after the start of treatment. Nine patients were treated by a continuous infusion pump, 9 other patients received sc injections 3 times daily, and 1 patient received both administration routes during the preoperative period. Treatment was discontinued the day before surgery, the mean duration of pretreatment was 5.2 ± 0.8 months (range, 1-17 months). The mean age of the pretreated patient group was 39.3 ± 9 yr (range, 19-52 yr). One of the patients had undergone transsphenoidal surgery 3 yr previously in Turkey. None of the other patients had been previously treated with irradiation or surgery. Nineteen patients (11 males and 8 females)
were matched to the octreotide-treated patients by tumor classifi cation and preoperative mean GH level. Their mean age was 47.7 ± 15.6 yr (range, 25-77 yr).
All patients underwent an endocrine assessment preoperatively, including a serum GH profi le (blood samples taken at 0800, 1130, 1630, and 2300 h), a 75-g oral glucose loading test (blood samples taken at 0, 30, 60, 90, and 120 min), and a 200-µg iv TRH test (blood samples taken at 0, 20, and 60 min), and pretreated patients underwent a 50-µg iv octreotide test, with samples taken every 30 min during 3 h. During the octreotide test, the lowest GH level was taken as the minimal value. The minimal value during this test was also expressed as a percentage of the starting GH value.
Other pituitary functions were evaluated by specifi c pituitary stimulation tests (LHRH, TRH, and CRH tests) and by measurement of serum testosterone, estradiol, cortisol, T 4 , and IGF-I.
Postoperative hormonal evaluation was performed 7-10 days after surgery by repeating the glucose tolerance (GTT) and TRH tests and measuring the IGF-I concentration and other pituitary reserve functions. At yearly follow-up visits, the GTT and measurements of mean GH and IGF-I concentrations were repeated, and evaluation of other pituitary functions was also performed. In this study the most recent hormonal investigations were used as follow-up results. Group characteristics are shown in Table 1 .
All patients underwent magnetic resonance imaging scanning of the sellar region. Adenomas were classifi ed as microadenoma (<1 cm), macroadenoma (> 1 cm), or invasive adenoma (into the sellafl oor, parasellar extension, or growth into the cavernous sinus).
Transsphenoidal surgery was performed by the same neurosurgeon (H.v.D.). Postoperatively, patients stayed on the neurosurgical ward for 6-9 days. Thereafter, they were transferred to the endocrinological ward, where the postoperative tests were performed.
The protocol was performed in accordance with the guidelines of the Declaration of Helsinki for human experimental studies. Informed consent was obtained from all patients.
Assays
Before 1992, serum GH was measured by RIA (Biolab/Serono, Coinsins, Switzerland) cali- 
Statistics
Calculations were performed using SPSS Windows version 6.0 (SPSS, Inc., Chicago, IL), using Student's t (paired), χ 2 , and ANOVA tests. Data were reported as the mean ± SEM (range), unless otherwise mentioned. P < 0.05 was considered signifi cant. Table 1 and Fig. 1 ). In the pretreated group, fi ve patients had microadenoma, eight patients noninvasive macroadenoma (2 0 , n = 2; 2 A , n = 4; 2 B , n = 2), and six patients an invasive macroadenoma (3 A , n = 1; 4 E , n = 3; 2 E , n = 2). The untreated group had the following tumor classifi cation: fi ve patients microadenoma, eight patients had noninvasive macroadenoma (2 0 , n = 3; 2 A , n = 4; 2 B , n = 1), and six patients had invasive adenomas (2 E , n = 2; 3 0 , n = 1; 3 A , n = 1; 3 E , n = 1; 4 DE , n = 1). The mean preoperative serum IGF-I levels were 64.6 ± 4.6 nmol/L in the treated patients and 47.6 ± 3.1 nmol/L in the untreated patients (P < 0.001; see Fig. 2 ).
Expressed as SD scores, these were 8.4 ± 0.9 and 5.5 ± 0.6 (P < 0.001), respectively (Fig. 3 ).
An octreotide test was performed in 17 treated patients. During this test, serum GH levels Postoperative mean serum GH concentrations were 7.11 ± 2.23 mU/L in the treated patients and 5.99 ± 2.09 mU/L in the untreated group (P = 0.72; Table 2 and Fig. 1 ). The mean glucose-suppressed GH concentration was 3.16 ± 1.08 mU/L in pretreated patients and 3.16 ± 1.46 mU/L in control patients (P = 0.99). The mean serum IGF-I concentrations were 31 ± 2.4 and 24.3 ± 2.0 nmol/L, respectively (P = 0.037; Fig. 2 ), and mean IGF-I SD scores were 2.0 ± 0.4 and 1.0 ± 0.37, respectively (P = 0.07; Fig. 3 ).
In terms of normalization, direct postoperative results were as follows. Serum GH concentrations were less than 5 mU/L in 15 treated and 14 untreated patients (P = 0.
7). A normal
Preoperative octreotide treatment 77 suppression of serum GH during GTT was achieved in 12 treated patients and 14 untreated patients (P = 0.5). The IGF-I SD score normalized in 10 treated and 15 untreated patients (P = 0.08).
During follow-up, seven pretreated and fi ve untreated patients required adjuvant therapy.
Radiotherapy was given to six pretreated patients and three untreated controls; postoperative octreotide therapy was given to one pretreated patient and two untreated patients. In Figure 1 . Mean GH concentrations (±SEM) at preoperative evaluation (pretreated and untreated patients), during octreotide treatment (pretreated patients), and directly postoperatively (pretreated and untreated patients). Black bars, Octreotide-treated patients; hatched bars, untreated patients. addition, two pretreated patients and one untreated patient received octreotide therapy in combination with radiotherapy.
After a follow-up period of 5.7 ± 0.5 yr (treated group) and 4.0 ± 0.6 yr (untreated group), 13 of 17 pretreated patients had normal suppression during GTT compared to 13 of 17 untreated patients (P = 1.0; see Table 3 of 12 pretreated patients and 13 of 14 control patients (P = 0.3). As expected, surgical cure rates were higher in microadenomas (90%) and noninvasive macroadenomas (75%) than in invasive macroadenomas (17%) group (P = 0.01; data summarized in Table 4 ).
The mean duration of stay on the neurosurgical ward postoperatively was not signifi cantly diff erent between pretreated and untreated patients, i.e. 8.2 (median 8) and 7.1 (median 7)
days, respectively (P = 0.06). Hormone substitution for (pan)hypopituitarism caused by surgery was necessary for two patients in each group.
Complications of surgery were reoperation for persistent cerebrospinal fl uid rhinorrhea (one pretreated patient), meningitis (one pretreated patient), and temporary cerebrospinal fl uid rhinorrhea (one pretreated patient). 
DISCUSSION
In our group of 19 pretreated acromegalic patients, octreotide suppressed the mean GH concentration to 30% of the pretreatment value. However, a "safe" GH concentration, i.e. be- MT, postoperative octreotide therapy; RT, radiotherapy. 1 Normal values of suppressed GH during GTT are < 2.5 mU/L before 1993 (RIA-assay) and < 1 mU/L thereafter (IFMA-assay).
patients. We did not measure clinical parameters during octreotide therapy, as was done by others (5, 6, 12) . Amelioration of signs and symptoms was claimed to facilitate anesthesia (5).
Colao et al. (6) reported a decreased blood pressure and an improved glucose profi le during octreotide treatment, thereby possibly reducing surgical risk and resulting in a shorter stay in the hospital. In our patients we found a low complication rate, with no clinical diff erence between groups. In addition, the length of stay on the neurosurgical ward was not signifi cantly diff erent between treated and untreated patients.
Because of logistic restrictions we could not repeat the magnetic resonance imaging scan of the sellar fossa preoperatively to evaluate the eff ect of octreotide treatment on tumor size. In summary, we could not demonstrate a diff erence in outcome between pretreated and untreated patients, either directly postoperatively or at follow-up examination.
